ArticleOrphanet journal of rare diseases2025

Results of a non-randomized, open-label phase I study evaluating the novel immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa.

Karl Wallblom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.